Barriers to hepatitis B virus screening of pregnant women in primary healthcare centers in Nigeria: health workers' perspective.
Challenges
Perinatal
Prevention of mother-to-child
Testing
Viral hepatitis
Journal
BMC primary care
ISSN: 2731-4553
Titre abrégé: BMC Prim Care
Pays: England
ID NLM: 9918300889006676
Informations de publication
Date de publication:
17 10 2023
17 10 2023
Historique:
received:
16
12
2022
accepted:
12
09
2023
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
epublish
Résumé
Hepatitis B virus (HBV) screening is an important component of antenatal care for pregnant women in Nigeria. However, the screening rates remain low, particularly at primary healthcare centers (PHCs). The objective of this study was to identify the barriers affecting antenatal HBV screening in PHCs in Nigeria from the perspective of health workers. We conducted a survey among 30 health workers from 30 PHCs (one per PHC) across three states (Akwa Ibom, Anambra, and Kaduna) in Nigeria. An open-ended questionnaire was used to obtain written responses on the perceived barriers limiting antenatal HBV screening in PHCs and their recommended solutions to the identified barriers. The data were analyzed using an inductive thematic approach. The perceived barriers exist at patient, provider and health system levels. They included: lack of test kits, unaffordability of HBV test, shortage of trained personnel, poor awareness among pregnant women, knowledge of HBV among health workers, high cost of antiviral treatment, and unavailability of HBV vaccine. The recommended solutions to the identified barriers were: making test kits and vaccines available and free, creating awareness about HBV, and capacity-building interventions for health workers. HBV screening of pregnant women attending PHCs in Nigeria appears to be affected by multilevel barriers. As the country continues to work towards eliminating HBV, these highlighted barriers at the patient, provider and health system levels must be addressed through effective and sustainable interventions.
Sections du résumé
BACKGROUND
Hepatitis B virus (HBV) screening is an important component of antenatal care for pregnant women in Nigeria. However, the screening rates remain low, particularly at primary healthcare centers (PHCs). The objective of this study was to identify the barriers affecting antenatal HBV screening in PHCs in Nigeria from the perspective of health workers.
METHODS
We conducted a survey among 30 health workers from 30 PHCs (one per PHC) across three states (Akwa Ibom, Anambra, and Kaduna) in Nigeria. An open-ended questionnaire was used to obtain written responses on the perceived barriers limiting antenatal HBV screening in PHCs and their recommended solutions to the identified barriers. The data were analyzed using an inductive thematic approach.
RESULTS
The perceived barriers exist at patient, provider and health system levels. They included: lack of test kits, unaffordability of HBV test, shortage of trained personnel, poor awareness among pregnant women, knowledge of HBV among health workers, high cost of antiviral treatment, and unavailability of HBV vaccine. The recommended solutions to the identified barriers were: making test kits and vaccines available and free, creating awareness about HBV, and capacity-building interventions for health workers.
CONCLUSIONS
HBV screening of pregnant women attending PHCs in Nigeria appears to be affected by multilevel barriers. As the country continues to work towards eliminating HBV, these highlighted barriers at the patient, provider and health system levels must be addressed through effective and sustainable interventions.
Identifiants
pubmed: 37848814
doi: 10.1186/s12875-023-02157-8
pii: 10.1186/s12875-023-02157-8
pmc: PMC10580522
doi:
Substances chimiques
Hepatitis B Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
209Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
PLoS One. 2021 Oct 29;16(10):e0259218
pubmed: 34714888
Int J STD AIDS. 2021 Dec;32(14):1290-1297
pubmed: 34387113
Open Forum Infect Dis. 2015 Sep 01;2(4):ofv122
pubmed: 26566533
Clin Infect Dis. 1995 Apr;20(4):992-1000
pubmed: 7795104
BMC Health Serv Res. 2017 Mar 1;17(1):172
pubmed: 28249578
Hum Resour Health. 2022 Jan 28;19(Suppl 1):108
pubmed: 35090481
Lancet Glob Health. 2015 Jul;3(7):e358-9
pubmed: 26087980
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):696
pubmed: 29143609
Expert Rev Anti Infect Ther. 2004 Feb;2(1):133-45
pubmed: 15482178
J Obstet Gynaecol. 2013 Feb;33(2):155-9
pubmed: 23445138
J Pediatr Gastroenterol Nutr. 2019 Dec;69(6):648-654
pubmed: 31503215
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403
pubmed: 29599078
Am J Trop Med Hyg. 2016 Dec 7;95(6):1368-1375
pubmed: 27928086
Aliment Pharmacol Ther. 2016 Nov;44(10):1005-1017
pubmed: 27630001
Trans R Soc Trop Med Hyg. 2022 Jul 6;116(7):604-608
pubmed: 35511955
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):702
pubmed: 29143612
Lancet. 2022 Jun 4;399(10341):2092
pubmed: 35658984
Cureus. 2022 Mar 7;14(3):e22928
pubmed: 35399450
Pan Afr Med J. 2016 Apr 06;23:160
pubmed: 27303576
JHEP Rep. 2023 Apr 24;5(8):100777
pubmed: 37554925
Health Syst Reform. 2016 Oct 1;2(4):302-318
pubmed: 31514724
Health Policy Plan. 2020 Nov 1;35(Supplement_1):i97-i106
pubmed: 33165588
Hepat Res Treat. 2015;2015:439867
pubmed: 25685549
BMC Health Serv Res. 2019 Sep 4;19(1):627
pubmed: 31484515
MMWR Morb Mortal Wkly Rep. 2023 Jul 21;72(29):782-787
pubmed: 37471264